Luciferase Reporter Cell Line - HSC3

HSC3 is a human oral squamous cell carcinoma cell line originally isolated from a metastatic lesion of the tongue. It is now widely used as an in vitro model to investigate the biological characteristics, tumor progression, mechanisms of invasion, epithelial malignant transformation, and therapeutic responses associated with oral cancer. HSC3 cells are distinguished by their aggressive phenotype, robust invasive capabilities, and significant relevance in the study of head and neck squamous cell carcinoma, making them an invaluable tool for researching cancer metastasis, signal transduction, gene regulation, and drug sensitivity. The HSC3 Luciferase Reporter Cell Line is an engineered derivative of the parental HSC3 line, stably modified to express a luciferase reporter gene. Through stable genomic integration and rigorous selection, this reporter cell line maintains consistent levels of luciferase expression throughout routine culture and experimental applications.

The HSC3 Luciferase Reporter Cell Line finds broad application across various fields of cancer research and drug development. In in vitro assays, the bioluminescent signal generated by these cells serves as a convenient surrogate marker for viable cell number, enabling researchers to perform cell proliferation assays, cytotoxicity testing, compound screening, and dose-response analyses with high sensitivity and a wide dynamic range. This makes the cell line an ideal tool for evaluating a diverse array of anticancer agents—including targeted inhibitors, chemotherapeutics, natural products, immunotherapies, and combination treatment strategies—specifically against oral squamous cell carcinoma. Given the highly invasive nature of HSC3 cells, the HSC3-Luc reporter line is also well-suited for investigating the mechanisms of cell migration and invasion, encompassing assays designed to assess tumor cell motility, extracellular matrix degradation, and metastatic potential. Within co-culture systems, the expression of luciferase enables the specific and quantitative detection of HSC3 tumor cells, even in the presence of stromal cells, fibroblasts, endothelial cells, immune cells, or other components of the tumor microenvironment.